Andrew Cittadine Monopar Therapeutics (MNPR) insider trading activity

Andrew Cittadine is Chief Operating Officer of Monopar Therapeutics. Currently has a direct ownership of 39,869 shares of MNPR, which is worth approximately $646,276. The most recent transaction as insider was on Dec 31, 2022, when has been sold 4,062 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 39.9K

79.35% 3M change

13.17% 12M change

Total Value Held $646,276

Andrew Cittadine Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 31 2022	BUY Exercise of conversion of derivative security	-	4,062 Added 12.55%	28,300 Common Stock
Nov 15 2022	BUY Open market or private purchase	$31,500 $3.15 p/Share	10,000 Added 29.21%	24,238 Common Stock
Nov 14 2022	BUY Open market or private purchase	$18,159 $3.0 p/Share	6,053 Added 29.83%	14,238 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$1,810 $1.52 p/Share	1,191 Reduced 12.7%	8,185 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	-	4,063 Added 30.23%	9,376 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$6,468 $2.3 p/Share	2,812 Reduced 34.61%	5,313 Common Stock
Jun 30 2022	BUY Exercise of conversion of derivative security	-	8,125 Added 50.0%	8,125 Common Stock

Andrew Cittadine

Chief Operating Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account